KX2-391 to Proceed Into Phase I Trials

Kinex Pharmaceuticals said its investigational new drug for cancer, KX2-391, will proceed into Phase I clinical trials.

Phase I trials of KX2-391 will start in September in patients with lymphoma or solid tumors. The goal of these studies is to generate human safety data and to look at potential efficacy using biomarkers, Kinex said.

According to the company, KX2-391 is an orally active Src kinase inhibitor with excellent bioavailability. It is a first-in-class drug because it is the first non-ATP competitive kinase inhibitor to enter human trials, thereby providing a highly selective mechanism of action that should have a decreased likelihood of inducing resistance in patients, the company added.